首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries.
【24h】

Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries.

机译:用基因修饰的自体肿瘤细胞免疫的黑色素瘤患者的抗黑色素瘤抗体:从单链Fv融合噬菌体文库中选择特异性抗体。

获取原文
获取原文并翻译 | 示例
           

摘要

Fusion phage libraries expressing single-chain Fv antibodies were constructed from the peripheral blood lymphocytes of two melanoma patients who had been immunized with autologous melanoma cells transduced the gamma-interferon gene to enhance immunogenicity, in a trial conducted at another institution. Anti-melanoma antibodies were selected from each library by panning the phage against live cultures of the autologous tumor. After two or three rounds of panning, clones of the phage were tested by ELISA for binding to the autologous tumor cells; > 90% of the clones tested showed a strong ELISA reaction, demonstrating the effectiveness of the panning procedure for selecting antimelanoma antibodies. The panned phage population was extensively absorbed against normal melanocytes to enrich for antibodies that react with melanoma cells but not with melanocytes. The unabsorbed phage were cloned, and the specificities of the expressed antibodies were individually tested by ELISA with a panel of cultured human cells. The first tests were done with normal endothelial and fibroblast cells to identify antibodies that do not react, or react weakly, with two normal cell types, indicating some degree of specificity for melanoma cells. The proportion of phage clones expressing such antibodies was approximately 1%. Those phage were further tested by ELISA with melanocytes, several melanoma lines, and eight other tumor lines, including a glioma line derived from glial cells that share a common lineage with melanocytes. The ELISA tests identified three classes of anti-melanoma antibodies, as follows: (i) a melanoma-specific class that reacts almost exclusively with the melanoma lines; (ii) a tumor-specific class that reacts with melanoma and other tumor lines but does not react with the normal melanocyte, endothelial and fibroblast cells; and (iii) a lineage-specific class that reacts with the melanoma lines, melanocytes, and the glioma line but does not react with the other lines. These are rare classes from the immunized patients' repertoires of anti-melanoma antibodies, most of which are relatively nonspecific anti-self antibodies. The melanoma-specific class was isolated from one patient, and the lineage-specific class was isolated from the other patient, indicating that different patients can have markedly different responses to the same immunization protocol. The procedures described here can be used to screen the antibody repertoire of any person with cancer, providing access to an enormous untapped pool of human monoclonal anti-tumor antibodies with clinical and research potential.
机译:在另一家机构进行的一项试验中,由两名黑色素瘤患者的外周血淋巴细胞构建了表达单链Fv抗体的融合噬菌体文库,这些患者已经用转导了γ-干扰素基因的自体黑色素瘤细胞进行了免疫,以增强免疫原性。通过淘选针对自体肿瘤的活培养物的噬菌体,从每个文库中选择抗黑素瘤抗体。经过两轮或三轮淘选后,通过ELISA测试噬菌体的克隆与自体肿瘤细胞的结合。超过90%的测试克隆显示出强大的ELISA反应,证明了淘选过程中选择抗炭疽抗体的有效性。淘选的噬菌体群体被正常黑色素细胞广泛吸收,以富集与黑色素瘤细胞但不与黑色素细胞反应的抗体。克隆未吸收的噬菌体,并用一组培养的人类细胞通过ELISA分别测试表达的抗体的特异性。最初的测试是对正常的内皮细胞和成纤维细胞进行的,以鉴定与两种正常细胞不发生反应或反应较弱的抗体,这表明其对黑素瘤细胞具有一定程度的特异性。表达此类抗体的噬菌体克隆的比例约为1%。这些噬菌体用黑色素细胞,几种黑色素瘤细胞系和其他八种肿瘤细胞系(包括源自与黑色素细胞共有谱系的神经胶质细胞衍生的神经胶质瘤细胞系)通过ELISA进行了进一步测试。 ELISA测试确定了三类抗黑素瘤抗体,如下:(i)一种几乎只与黑素瘤系反应的黑素特异性抗体; (ii)与黑色素瘤和其他肿瘤细胞发生反应但不与正常的黑色素细胞,内皮细胞和成纤维细胞反应的肿瘤特异性类别; (iii)与黑色素瘤系,黑色素细胞和神经胶质瘤系反应但不与其他系反应的特定谱系类别。这些是免疫患者抗黑素瘤抗体库中的罕见类,其中大多数是相对非特异性的抗自身抗体。从一名患者中分离出黑素瘤特异性类别,从另一名患者中分离出谱系特异性类别,这表明不同患者对同一免疫方案的反应可能明显不同。此处描述的程序可用于筛选任何癌症患者的抗体库,从而提供具有临床和研究潜力的巨大未开发人类单克隆抗肿瘤抗体库。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号